Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie and Genmab have initiated a real-world study titled ‘EpcoReal’ to evaluate the effectiveness of subcutaneous epcoritamab in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). This study aims to provide insights into the drug’s performance in a real-world setting, focusing on patients with advanced stages of these lymphomas.
The intervention being tested is epcoritamab, an investigational drug designed to treat DLBCL and FL. It is administered subcutaneously and is intended to improve outcomes for patients with these types of non-Hodgkin lymphoma.
The study is observational in nature, following a cohort model with a prospective time perspective. Participants will receive epcoritamab as per their physician’s prescription, and the study will observe their progress over three years without additional burdens beyond routine clinical visits.
The study began on March 28, 2025, with its primary completion and estimated completion dates yet to be determined. The most recent update was submitted on July 18, 2025, indicating ongoing recruitment and study activities.
This study could significantly impact AbbVie and Genmab’s stock performance, as successful outcomes may enhance investor confidence and market position in the competitive oncology sector. The ongoing recruitment and updates suggest a commitment to advancing treatment options for lymphoma patients.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.